View:
Download DOC
Download PDF
Download XLS
DEFA14A

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 

 

SCHEDULE 14A

(Rule 14a-101)

INFORMATION REQUIRED IN PROXY STATEMENT

SCHEDULE 14A INFORMATION

Proxy Statement Pursuant to Section 14(a) of the

Securities Exchange Act of 1934

 

 

Filed by the Registrant   ☒                             Filed by a Party other than the Registrant   ☐

Check the appropriate box:

 

☐    Preliminary Proxy Statement
☐    Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
☐    Definitive Proxy Statement
☒    Definitive Additional Materials
☐    Soliciting Material Pursuant to § 240.14a-12

ZIOPHARM Oncology, Inc.

(Name of Registrant as Specified in Its Charter)

(Name of Person(s) Filing Proxy Statement, if Other Than the Registrant)

Payment of Filing Fee (Check the appropriate box):

 

☒    No fee required.
☐    Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.
   (1)   

Title of each class of securities to which transaction applies:

 

     

   (2)   

Aggregate number of securities to which transaction applies:

 

     

   (3)   

Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):

 

     

   (4)   

Proposed maximum aggregate value of transaction:

 

     

   (5)   

Total fee paid:

 

     

☐    Fee paid previously with preliminary materials:
☐    Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.
   (1)   

Amount previously paid:

 

     

   (2)   

Form, Schedule or Registration Statement No.:

 

     

   (3)   

Filing Party:

 

     

   (4)   

Date Filed:

 

     

 

 

 

*** Exercise Your Right to Vote ***

Important Notice Regarding the Availability of Proxy Materials for the

Stockholder Meeting to Be Held on June 14, 2017

 

 

 

ZIOPHARM ONCOLOGY, INC.

 
 

 

ZIOPHARM ONCOLOGY, INC.

ATTN: CORPORATE SECRETARY

ONE FIRST AVENUE, PARRIS BLDG #34

THIRD FLOOR, NAVY YARD PLAZA

BOSTON, MA 02129

  
   
   
   
   
   
   
   
   
           
  Meeting Information    
 

 

  Meeting Type:  Annual Meeting

 

    
 

  For holders as of:  April 18, 2017

 

    
 

  Date:  June 14, 2017        

 

   Time:  10:00 AM EDT    
    Location:    One First Avenue    
 

 

                         Parris Building 34

 

                         Third Floor

 

                         Navy Yard Plaza

 

                         Boston, Massachusetts 02129

 

    
          
 

 

You are receiving this communication because you hold shares in the above named company.

 

 

This is not a ballot. You cannot use this notice to vote these shares. This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. You may view the proxy materials online at www.proxyvote.com or easily request a paper copy (see reverse side).

 

 

We encourage you to access and review all of the important information contained in the proxy materials before voting.

 

 

 

See the reverse side of this notice to obtain proxy materials and voting instructions.

 

 

 

      

— Before You Vote —

How to Access the Proxy Materials

 

  
      

 

Proxy Materials Available to VIEW or RECEIVE:

    
      

1. Notice & Proxy Statement      2. Form 10-K

 

How to View Online:

Have the information that is printed in the box marked by the arrow   LOGO   (located on the following page) and visit: www.proxyvote.com.

 

How to Request and Receive a PAPER or E-MAIL Copy:

If you want to receive a paper or e-mail copy of these documents, you must request one. There is NO charge for requesting a copy. Please choose one of the following methods to make your request:

    
      

1) BY INTERNET:        www.proxyvote.com

    
      

2) BY TELEPHONE:    1-800-579-1639

    
      

3) BY E-MAIL*:             sendmaterial@proxyvote.com

    
      

 

*  If requesting materials by e-mail, please send a blank e-mail with the information that is printed in the box marked by the arrow LOGO (located on the following page) in the subject line.

 

Requests, instructions and other inquiries sent to this e-mail address will NOT be forwarded to your investment advisor. Please make the request as instructed above on or before May 31, 2017 to facilitate timely delivery.

 

    
          
        
      

— How To Vote —

Please Choose One of the Following Voting Methods

 

  
            
      

Vote In Person: Many stockholder meetings have attendance requirements including, but not limited to, the possession of an attendance ticket issued by the entity holding the meeting. Please check the meeting materials for any special requirements for meeting attendance. At the meeting, you will need to request a ballot to vote these shares.

 

Vote By Internet: To vote now by Internet, go to www.proxyvote.com. Have the information that is printed in the box marked by the arrow LOGO available and follow the instructions.

    
      

 

Vote By Mail: You can vote by mail by requesting a paper copy of the materials, which will include a proxy card.

 

    
            

Voting items      

The Board of Directors recommends you vote

FOR the following:

   
1.   Election of Directors   
  Nominees   
01   Murray Brennan                02    James A. Cannon                03    Wyche Fowler, Jr.                04    Randal J. Kirk                05    Scott Tarriff
06   Michael Weiser
The Board of Directors recommends you vote FOR proposals 2 and 3.   
2.   To ratify the appointment of RSM US LLP as the Company’s independent registered public accounting firm for 2017   
3.   To approve, on an advisory basis, the compensation of the Company’s named executive officers as disclosed in the proxy statement   
The Board of Directors recommends you vote 1 YEAR on the following proposal:   
4.   To indicate, on an advisory basis, the preferred frequency of shareholder advisory votes on the compensation of the Company’s named executive officers   
NOTE:  To transact any other business as may properly come before the meeting or any adjournments or postponements thereof.